Adhera Therapeutics, Inc. - Quarter Report: 2019 September (Form 10-Q)

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q

(Mark One)



[X]	QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended: September 30, 2019



[ ]	TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from _____________ to _____________.

Commission File Number: 000-13789

ADHERA THERAPEUTICS, INC.

(Exact name of registrant as specified in its charter)



Delaware		11-2658569
(State or other jurisdiction of incorporation or organization)		(IRS Employer Identification No.)

4721 Emperor Boulevard, Suite 350 Durham, NC		27703
(Address of principal executive offices)		(Zip Code)

(919) 578-5901

(Registrant’s telephone number, including area code)

N/A

(Former name, former address and former fiscal year, if changed since last report)

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes [X] No [ ]

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes [X] No [ ]

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a small reporting company. See the definitions of “large accelerated filer”, “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act.



Large accelerated filer	[ ]	Accelerated filer	[ ]

Non-accelerated filer	[ ] (Do not check if a smaller reporting company)	Smaller reporting company	[X]

		Emerging Growth Company	[ ]

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act: [ ]

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes [ ] No [X].

As of November 12, 2019, there were 10,869,530 shares of the registrant’s common stock outstanding.

ADHERA THERAPEUTICS, INC.

FORM 10-Q

FOR THE QUARTERLY PERIOD ENDED SEPTEMBER 30, 2019

TABLE OF CONTENTS



		Page

PART I - FINANCIAL INFORMATION

ITEM 1	Financial Statements (unaudited)

	Condensed Consolidated Balance Sheets as of September 30, 2019 and December 31, 2018	3

	Condensed Consolidated Statements of Operations for the Three and Nine Months Ended September 30, 2019 and 2018	4

	Condensed Consolidated Statements of Stockholders’ Equity (Deficit) for the Nine Months Ended September 30, 2019 and 2018	5

	Condensed Consolidated Statements of Cash Flows for the Nine Months Ended September 30, 2019 and 2018	7

	Notes to Condensed Consolidated Financial Statements	8

ITEM 2.	Management’s Discussion and Analysis of Financial Condition and Results of Operations	19

ITEM 3.	Quantitative and Qualitative Disclosures about Market Risk	25

ITEM 4.	Controls and Procedures	25

PART II - OTHER INFORMATION

ITEM 1.	Legal Proceedings	26

ITEM 1A.	Risk Factors	27

ITEM 2.	Unregistered Sales of Equity Securities and Use of Proceeds	27

ITEM 3.	Defaults on Senior Securities	27

ITEM 4.	Mine Safety Disclosures	27

ITEM 5.	Other Information	28

ITEM 6.	Exhibits	28

SIGNATURES		29

PART I – FINANCIAL INFORMATION

ITEM 1. CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

ADHERA THERAPEUTICS, INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED BALANCE SHEETS

(in thousands, except for share and per share amounts)



	September 30, 2019			December 31, 2018
	(Unaudited)
ASSETS
Current assets
Cash	$	2,692		$	3,918
Accounts receivable, net of allowance	90			48
Inventory	473			242
Prepaid expenses and other assets	323			469
Total current assets	3,578			4,677
Operating lease right of use asset	157			—
Furniture and fixtures, net of depreciation	62			72
Intangible assets, net of amortization	339			392
	558			464
Total assets	$	4,136		$	5,141
LIABILITIES AND STOCKHOLDERS’ EQUITY (DEFICIT)

Current liabilities
Accounts payable	$	876		$	270
Due to related party	4			28
Accrued expenses	1,135			852
Current portion of operating lease liability	77			—
Accrued dividends	2,189			1,064
Notes payable	5,151			—
Total current liabilities	9,432			2,214
Operating lease liability, net of current portion	88			—
Total liabilities	9,520			2,214
Commitments and contingencies (Note 9)
Stockholders’ equity (deficit)
Preferred stock, $0.01 par value; 100,000 shares authorized
Series C convertible preferred stock, $0.01 par value; $5,100 liquidation preference; 1,200 shares authorized; 100 shares issued and outstanding as of September 30, 2019 and December 31, 2018	—			—
Series D convertible preferred stock, $0.01 par value; $300 liquidation preference; 220 shares authorized; 40 shares issued and outstanding as of September 30, 2019 and December 31, 2018	—			—
Series E convertible preferred stock, $0.01 par value; $5,000 liquidation preference; 3,500 shares authorized; 3,478 and 3,488 shares issued and outstanding as of September 30, 2019 and December 31, 2018, respectively	—			—
Series F convertible preferred stock, $0.01 par value; $5,000 liquidation preference; 2,200 shares authorized; 381 shares issued and outstanding as of September 30, 2019 and December 31, 2018	—			—
Common stock, $0.006 par value; 180,000,000 shares authorized, 10,869,530 and 10,761,684 shares issued and outstanding as of September 30, 2019 and December 31, 2018, respectively	65			65
Additional paid-in capital	29,418			28,710
Accumulated deficit	(34,867		)	(25,848		)
Total stockholders’ equity (deficit)	(5,384		)	2,927
Total liabilities and stockholders’ equity (deficit)	$	4,136		$	5,141

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

ADHERA THERAPEUTICS, INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

(Unaudited)

(in thousands, except for share and per share amounts)



	For the Three Months Ended September 30,						For the Nine Months Ended September 30,
	2019			2018			2019			2018
Net sales	$	51		$	135		$	120		$	135
Cost of sales	106			67			304			67
Gross margin	(55		)	68			(184		)	68
Operating expenses
Sales and marketing	1,311			871			3,518			3,457
Research and development	—			—			—			173
General and administrative	840			2,141			3,806			4,120
Goodwill and intangible asset impairment	—			4,794			—			4,794
Amortization	18			41			53			288
Total operating expenses	2,169			7,847			7,377			12,832
Loss from operations	(2,224		)	(7,779		)	(7,561		)	(12,764		)
Other expense
Interest expense	(332		)	—			(333		)	(149		)
Loss on settlement	—			—			—			(875		)
Loss before provision for income taxes	(2,556		)	(7,779		)	(7,894		)	(13,788		)
Provision for income taxes	—			—			—			—
Net loss	(2,556		)	(7,779		)	(7,894		)	(13,788		)
Preferred Stock Dividends	(389		)	(379		)	(1,128		)	(650		)
Net Loss Applicable to Common Stockholders	$	(2,945	)	$	(8,158	)	$	(9,022	)	$	(14,438	)
Net loss per share – Common Shareholders - basic and diluted	$	(0.27	)	$	(0.73	)	$	(0.83	)	$	(1.33	)
Weighted average shares outstanding - basic and diluted	10,869,530			11,241,684			10,830,816			10,864,036

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

ADHERA THERAPEUTICS, INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENT OF STOCKHOLDERS’ EQUITY (DEFICIT)

(in thousands, except for share amounts)



	Series E Preferred Stock					Series F Preferred Stock			Common Stock			Additional Paid-in Capital			Additional Paid-in Capital Warrants		Accumulated Deficit			Total
	Number			Par Value		Number	Par Value		Number	Par Value		Additional Paid-in Capital			Additional Paid-in Capital Warrants		Accumulated Deficit			Total
Balance, December 31, 2017	—			$	—	—	$	—	10,521,278	$	63	$	8,414		$	—	$	(8,029	)	$	448
Share based compensation	—			—		—	—		—	—		119			—		—			119
Net loss	—			—		—	—		—	—		—			—		(1,361		)	(1,361		)
Balance, March 31, 2018	—			—		—	—		10,521,278	63		8,533			—		(9,390		)	(794		)
Issuance of Series E Preferred Stock, net of fees	2,812			—		—	—		—	—		12,258			—		—			12,258
Warrants issued with Series E Preferred Stock	—			—		—	—		—	—		(31,107		)	31,107		—			—
Issuance of Series E Preferred for debt and accounts payable	687			—		—	—		—	—		3,438			—		—			3,438
Conversion of Series C Preferred stock for common stock	—			—		—	—		433,334	3		(3		)	—		—			—
Conversion of Series D Preferred stock for common stock	—			—		—	—		25,000	—		—			—		—			—
Warrants issued for settlement of liability	—			—		—	—		—	—		—			1,494		—			1,494
Shares issued for settlement of litigation	—			—		—	—		210,084	1		249			—		—			250
Shares issued for License Agreement	—			—		—	—		51,988	—		75			—		—			75
Accrued dividend	—			—		—	—		—	—		—			—		(271		)	(271		)
Share based compensation	—			—		—	—		—	—		374			—		—			374
Cancellation of Series E Preferred Stock	(9	)		—		—	—		—	—		(46		)	—		—			(46		)
Net loss	—			—		—	—		—	—		—			—		(4,648		)	(4,648		)
Balance, June 30, 2018	3,490			—		—	—		11,241,684	67		(6,229		)	32,601		(14,309		)	12,130
Issuance of Series E Preferred Stock, net of fees	—			—		—	—		—	—		(11		)	—		—			(11		)
Issuance of Series F Preferred Stock, net of fees	—			—		308	—		—	—		1,339			—		—			1,339
Warrants issued with Series F Preferred stock	—			—		—	—		—	—		(1,314		)	1,314		—			—
Accrued dividend	—			—		—	—		—	—		—			—		(379		)	(379		)
Share based compensation	—			—		—	—		—	—		814			—		—			814
Net loss	—			—		—	—		—	—		—			—		(7,779		)	(7,779		)
Balance, September 30, 2018	3,490		3,490	$	—	308	$	—	11,241,684	$	67	$	(5,401	)	$	33,915	$	(22,467	)	$	6,114



	Series E Preferred Stock				Series F Preferred Stock			Common Stock			Additional Paid-in Capital			Additional Paid-in Capital Warrants		Accumulated Deficit			Total
	Number		Par Value		Number	Par Value		Number	Par Value		Additional Paid-in Capital			Additional Paid-in Capital Warrants		Accumulated Deficit			Total
Balance, December 31, 2018	3,488		$	—	381	$	—	10,761,684	$	65	$	(5,384	)	$	34,094	$	(25,848	)	$	2,927
Accrued dividend	—		—		—	—		—	—		—			—		(382		)	(382		)
Share based compensation	—		—		—	—		—	—		395			—		—			395
Net loss	—		—		—	—		—	—		—			—		(2,558		)	(2,558		)
Balance, March 31, 2019	3,488		—		381	—		10,761,684	65		(4,989		)	34,094		(28,788		)	382
Conversion of Series E Preferred stock for common stock	(10	)	—		—	—		107,846	—		—			—		3			3
Accrued dividend	—		—		—	—		—	—		—			—		(357		)	(357		)
Share based compensation	—		—		—	—		—	—		241			—		—			241
Net loss			—			—			—		—			—		(2,780		)	(2,780		)
Balance, June 30, 2019	3,478		—		381	—		10,869,530	65		(4,748		)	34,094		(31,922		)	(2,511		)
Accrued dividend	—		—		—	—		—	—		—			—		(389		)	(389		)
Share based compensation	—		—		—	—		—	—		72			—		—			72
Net loss	—		—		—	—		—	—		—			—		(2,556		)	(2,556		)
Balance, September 30, 2019	3,478		$	—	381	$	—	10,869,530	$	65	$	(4,676	)	$	34,094	$	(34,867	)	$	(5,384	)

The accompanying notes are an integral part of these consolidated financial statements.

ADHERA THERAPEUTICS, INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(Unaudited)

(in thousands)



	For the Nine Months Ended September 30,
	2019			2018
Cash Flows Used in Operating Activities:
Net loss	$	(7,894	)	$	(13,788	)
Adjustments to reconcile net loss to net cash used in operating activities:
Share based compensation	708			1,307
Common shares issued for settlement	—			250
Preferred shares issued for note settlement	—			375
Common shares issued for license agreement	—			75
Goodwill and intangible asset impairment	—			4,794
Amortization of intangibles	53			288
Bad debt expense	(14		)	—
Amortization of debt discount	—			113
Depreciation	10			—
Non-cash interest expense	152			37
Non-cash lease expense	83			—
Amortization of debt issuance cost	181			—
Loss on settlement	—			875
Changes in operating assets and liabilities:
Accounts receivable	(28		)	(135		)
Inventory	(231		)	(204		)
Prepaid expenses and other assets	146			(430		)
Accounts payable	605			(123		)
Accrued expenses	142			(641		)
Accrued fee payable	—			(320		)
Deferred revenue	—			200
Due to related party	(24		)	313
Lease liability	(85		)	—
Net Cash Used in Operating Activities	(6,196		)	(7,014		)
Cash Flows Used in Investing Activities:
Purchase of furniture and fixtures	—			(28		)
Net Cash Used in Investing Activities	—			(28		)
Cash Flows Provided By Financing Activities:
Proceeds from sale of preferred stock, net offering expenses	—			13,586
Proceeds from loan payable	5,677			—
Loan payable issuance costs	(707		)	—
Payments for notes payable	—			(144		)
Net Cash Provided by Financing Activities	4,970			13,442
Net (decrease) increase in cash	(1,226		)	6,400
Cash – Beginning of Period	3,918			106
Cash - End of Period	$	2,692		$	6,506
Supplemental Cash Flow Information:
Non-cash Investing and Financing Activities:
Capitalization of operating lease right of use asset	$	240		$	—
Issuance of warrants for liabilities, related party	—			1,494
Preferred share settlement of debt and accrued liabilities	—			3,438
Issuance of warrants	—			32,421
Accrued dividends	1,128			650
Conversion of Series E Preferred stock for common stock	3			46
Goodwill reclassified to inventory	—			161

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

ADHERA THERAPEUTICS, INC. AND SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

FOR THE THREE AND NINE MONTHS ENDED SEPTEMBER 30, 2019

(Unaudited)

Note 1 – Nature of Operations, Basis of Presentation and Significant Accounting Policies

Business Overview

Adhera Therapeutics, Inc. (formerly known as Marina Biotech, Inc.) and its wholly-owned subsidiaries, MDRNA Research, Inc. (“MDRNA”), Cequent Pharmaceuticals, Inc. (“Cequent”), Atossa Healthcare, Inc. (“Atossa”), and IThenaPharma, Inc. (“IThena”) (collectively “Adhera,” the “Company,) is an emerging specialty pharmaceutical company that leverages innovative distribution models and technologies to improve the quality of care for patients in the United States suffering from chronic diseases. The Company is focused on fixed dose combination (“FDC”) therapies in hypertension, with plans to expand the portfolio of drugs being commercialized to include other therapeutic areas.

The Company’s mission is to provide effective and patient centric treatment for hypertension while actively seeking additional assets that can be commercialized through our proprietary Total Care System (“TCS”). At the core of the Company's TCS system is DyrctAxess, a patented technology platform. DyrctAxess is designed to offer enhanced efficiency, control and access to the information necessary to empower patients, physicians and manufacturers to achieve optimal care.

The Company is focused on demonstrating the therapeutic and commercial value of TCS through the commercialization of Prestalia^®, a single-pill FDC of perindopril arginine (“perindopril”) and amlodipine besylate (“amlodipine”) which is used as a first-line treatment for hypertension. Prestalia^® was developed by Les Laboratories, Servier, a French pharmaceutical conglomerate, that sells the formulation outside the United States under the brand names Coveram^® and/or Viacoram^®. Prestalia^® was approved by the U.S. Food and Drug Administration (“FDA”) in January 2015 and the license to such product was acquired by the Company from Symplmed in June 2017. By combining Prestalia^®, DyrctAxess and an independent pharmacy network, the Company has created a proprietary system for drug adherence including patient counseling and prescription reminder services, including the distribution of blood pressure monitors for therapeutic drug monitoring (“TDM”).

In 2018, the Company discontinued all significant clinical development activities and is evaluating disposition options for its development assets, including but not limited to: (i) a next generation celecoxib program of drug candidates for the treatment of acute and chronic pain; (ii) an FDC used to suppress polyps in the precancerous syndrome and orphan indication Familial Adenomatous Polyposis; (iii) an FDC to treat Colorectal Cancer; and (iv) an FDC for irritable bowel disease (IBD). The Company plans to license or divest these development assets since they no longer align with the Company’s focus on the commercialization of Prestalia and other products.

On September 4, 2019, the Company entered into a Co-Promotion Agreement with Allegis Pharmaceuticals, LLC (“Allegis”) to co-promote Allegis’ FDA approved product Nitrolingual^® Pumpspray indicated for acute relief of an attack or prophylaxis of angina pectoris due to coronary artery disease. The Co-Promotion Agreement relates to both the branded and the authorized generic versions of the product.

Basis of Presentation

The accompanying condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America for interim financial information and in accordance with the instructions pursuant to the rules and regulations of the Securities and Exchange Commission. Accordingly, they do not include all of the information and note disclosures required by U.S. generally accepted accounting principles (“U.S. GAAP”) for complete audited financial statements. This quarterly report should be read in conjunction with the consolidated financial statements in the Company’s Annual Report on Form 10-K for the year ended December 31, 2018. The information furnished in this report reflects all adjustments (consisting of normal recurring adjustments), which are, in the opinion of management, necessary for a fair presentation of our financial position, results of operations and cash flows for each period presented. The results of operations for the three or nine months ended September 30, 2019 are not necessarily indicative of the results for the year ending December 31, 2019 or for any future period.

Principles of Consolidation

The condensed consolidated financial statements include the accounts of Adhera Therapeutics, Inc. and the wholly-owned subsidiaries, Ithena, Cequent, MDRNA, and Atossa, and eliminate any inter-company balances and transactions.

Going Concern and Management’s Liquidity Plans

The accompanying condensed consolidated financial statements have been prepared on the basis that the Company will continue as a going concern, which contemplates realization of assets and the satisfaction of liabilities in the normal course of business. As of September 30, 2019, the Company had cash and cash equivalents of $2.7 million and has negative working capital of approximately $5.9 million.

The Company has incurred recurring losses and negative cash flows from operations since inception and has funded its operating losses through the sale of common stock, preferred stock, warrants to purchase common stock, convertible notes and secured promissory notes. The Company incurred a net operating loss of approximately $2.6 million and $7.9 million for the three and nine months ended September 30, 2019, respectively. The Company had an accumulated deficit of approximately $34.9 million as of September 30, 2019.

The Company expects to continue to incur operating losses as it executes the commercialization plans for Prestalia®, as well as other strategic and business development initiatives. If the Company is unable to obtain additional financing in the future, there may be a negative impact on the financial viability of the Company. The Company plans to increase working capital by managing its cash flows and expenses, divesting development assets and raising additional capital through private or public equity or debt financing. There can be no assurance that such financing or partnerships will be available on terms which are favorable to the Company or at all. While management of the Company believes that it has a plan to fund ongoing operations, there is no assurance that its plan will be successfully implemented. Failure to raise additional capital through one or more financings, divesting development assets or reducing discretionary spending could have a material adverse effect on the Company’s ability to achieve its intended business objectives. These factors raise substantial doubt about the Company’s ability to continue as a going concern. The condensed consolidated financial statements do not contain any adjustments that might result from the resolution of any of the above uncertainties.

Summary of Significant Accounting Policies

Use of Estimates

The preparation of the accompanying condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reported period. Significant areas requiring the use of management estimates include revenue and related discounts and allowances and accruals related to our operating activity including legal and other consulting expenses. Actual results could differ materially from such estimates under different assumptions or circumstances.

Compensating Balance Arrangements

The Company maintains a $50,000 short-term certificate of deposit as a compensating balance for the Company’s credit card. The certificate of deposit is classified as cash and cash equivalents in the accompanying balance sheet.

Reclassification

Certain reclassifications have been made to prior years' consolidated statements of operations to conform to current period presentation. These reclassifications had no effect on prior years' consolidated net loss or stockholders' deficit.

Fair Value of Financial Instruments

The Company considers the fair value of cash, accounts payable, accounts receivable and accrued expenses not to be materially different from their carrying value. These financial instruments have short-term maturities. We follow authoritative guidance with respect to fair value reporting issued by the Financial Accounting Standards Board (“FASB”) for financial assets and liabilities, which defines fair value, provides guidance for measuring fair value and requires certain disclosures. The guidance does not apply to measurements related to share-based payments. The guidance discusses valuation techniques, such as the market approach (comparable market prices), the income approach (present value of future income or cash flow), and the cost approach (cost to replace the service capacity of an asset or replacement cost). The guidance establishes a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value into three broad levels. The following is a brief description of those three levels:


Level 1:	Observable inputs such as quoted prices (unadjusted) in active markets for identical assets or liabilities.


Level 2:	Inputs other than quoted prices that are observable for the asset or liability, either directly or indirectly. These include quoted prices for similar assets or liabilities in active markets and quoted prices for identical or similar assets or liabilities in markets that are not active.


Level 3:	Unobservable inputs in which little or no market data exists, therefore developed using estimates and assumptions developed by us, which reflect those that a market participant would use.

There were no liabilities or assets measured at fair value as of September 30, 2019 or December 31, 2018.

Accounts Receivable, net

Accounts receivable consists of amounts due from wholesale distributors and specialty pharmacy providers. The Company records an allowance for doubtful accounts at the time potential collection risk is identified. The Company estimates its allowance based on historical experience, assessment of specific risks and discussions with individual customers. The Company believes the reserve is adequate to mitigate current collection risks. During the three and nine months ended September 30, 2019, the Company recorded a reduction in the allowance of approximately $55,000 and $14,000, respectively. The Company recorded no allowance for the three or nine months ended September 30, 2018.

Goodwill and Intangible Assets

The Company periodically reviews the carrying value of intangible assets, including goodwill, to determine whether impairment may exist. Goodwill and certain intangible assets are assessed annually, or when certain triggering events occur, for impairment using fair value measurement techniques. These events could include a significant change in the business climate, legal factors, a decline in operating performance, competition, sale or disposition of a significant portion of the business, or other factors. Specifically, goodwill impairment is determined using a two-step process. The first step of the goodwill impairment test is used to identify potential impairment by comparing the fair value of a reporting unit with its carrying amount, including goodwill. The Company uses level 3 inputs and a discounted cash flow methodology to estimate the fair value of a reporting unit. A discounted cash flow analysis requires one to make various judgmental assumptions including assumptions about future cash flows, growth rates, and discount rates. The assumptions about future cash flows and growth rates are based on the Company’s budget and long-term plans. Discount rate assumptions are based on an assessment of the risk inherent in the respective reporting units. If the fair value of a reporting unit exceeds its carrying amount, goodwill of the reporting unit is considered not impaired and the second step of the impairment test is unnecessary. If the carrying amount of a reporting unit exceeds its fair value, the second step of the goodwill impairment test is performed to measure the amount of impairment loss, if any. The second step of the goodwill impairment test compares the implied fair value of the reporting unit’s goodwill with the carrying amount of that goodwill. If the carrying amount of the reporting unit’s goodwill exceeds the implied fair value of that goodwill, an impairment loss is recognized in an amount equal to that excess. The implied fair value of goodwill is determined in the same manner as the amount of goodwill recognized in a business combination. That is, the fair value of the reporting unit is allocated to all of the assets and liabilities of that unit (including any unrecognized intangible assets) as if the reporting unit had been acquired in a business combination and the fair value of the reporting unit was the purchase price paid to acquire the reporting unit.

For the three and nine months ended September 30, 2018, the Company recognized a loss on impairment of an intangible asset including goodwill of approximately $4.8 million. The impairment determination was primarily a result of the decision to divest assets that no longer aligned with the Company’s strategic objectives.

No impairment charges were recognized for the three and nine-month period ended September 30, 2019.

Impairment of Long-Lived Assets

The Company reviews long-lived assets for impairment indicators throughout the year and performs detailed testing whenever impairment indicators are present. In addition, we perform detailed impairment testing for indefinite-lived intangible assets, at least annually, at December 31. When necessary, the Company records charges for impairments. Specifically:

•

For finite-lived intangible assets, such as developed technology rights, and for other long-lived assets, we compare the undiscounted amount of the projected cash flows associated with the asset, or asset group, to the carrying amount. If the carrying amount is found to be greater, we record an impairment loss for the excess of book value over fair value. In addition, in all cases of an impairment review, we re-evaluate the remaining useful lives of the assets and modify them, as appropriate; and


•	For indefinite-lived intangible assets, such as acquired in-process R&D assets, each year and whenever impairment indicators are present, we determine the fair value of the asset and record an impairment loss for the excess of book value over fair value, if any.

The Company did not recognize any loss on impairment for the three or nine-month periods ended September 30, 2019 or 2018.

Revenue Recognition

Customers Concentration

The Company operates in one segment and sells its prescription drug (Prestalia®) directly to specialty contracted retail pharmacies and indirectly through wholesalers. For the three months ended September 30, 2019, the Company’s three largest customers accounted for 22%, 20% and 13% of the Company’s total gross sales. For the nine months ended September 30, 2019, the Company’s three largest customers accounted for 30%, 28%, and 18% of the Company’s total gross sales. The Company works with a third-party pharmacy network manager to attract, retain, and manage the Company’s pharmacy customers and distribution channels. For the three and nine months months ended September 30, 2018, the Company’s three largest customers accounted for 42%, 36% and 12% of the Company’s total gross sales.

Revenue, Net

The Company adopted the new revenue recognition guidelines in accordance with ASC 606, Revenue from Contracts with Customers (ASC 606), effective with the quarter ended March 31, 2018.

The Company sells its medicines primarily to wholesale distributors and specialty pharmacy providers under agreements with payment terms typically less than 90 days. These customers subsequently resell the Company’s medicines to health care patients. Revenue is recognized when performance obligations under the terms of a contract with a customer are satisfied. The majority of the Company’s contracts have a single performance obligation to transfer medicines. Accordingly, revenues from medicine sales are recognized when the customer obtains control of the Company’s medicines, which occurs at a point in time, typically upon delivery to the customer. Revenue is measured as the amount of consideration the Company expects to receive in exchange for transferring medicines and is generally based upon a list or fixed price less allowances for medicine returns, rebates and discounts. Company records an estimate of unrealized revenue reductions, and the related liability, for bottles sold to pharmacies but not yet prescribed.

Medicine Sales Discounts and Allowances

The nature of the Company’s contracts gives rise to variable consideration because of allowances for medicine returns, rebates and discounts. Allowances for medicine returns, rebates and discounts are recorded at the time of sale to wholesale pharmaceutical distributors and pharmacies. The Company applies significant judgments and estimates in determining some of these allowances. If actual results differ from its estimates, the Company will be required to make adjustments to these allowances in the future. The Company’s adjustments to gross sales are discussed further below.

Patient Access Programs

The Company offers discounts to patients under which the patient receives a discount on his or her prescription. In circumstances when a patient’s prescription is rejected by a third-party payer, the Company will pay for the full cost of the prescription. The Company reimburses pharmacies for this discount directly or through third-party vendors. The Company reduces gross sales by the amount of actual co-pay and other patient assistance in the period based on the invoices received. The Company also records an accrual to reduce gross sales for estimated co-pay and other patient assistance on units sold to distributors or pharmacies that have not yet been prescribed/dispensed to a patient. The Company calculates accrued co-pay and other patient assistance fee estimates using the expected value method. The estimate is based on contract prices, estimated percentages of medicine that will be prescribed to qualified patients, average assistance paid based on reporting from the third-party vendors and estimated levels of inventory in the distribution channel. Accrued co-pay and other patient assistance fees are included in “accrued expenses” on the condensed consolidated balance sheet. Patient assistance programs include both co-pay assistance and fully bought down prescriptions.

Sales Returns

Consistent with industry practice, the Company maintains a return policy that allows customers to return medicines within a specified period prior to and subsequent to the medicine expiration date. Generally, medicines may be returned for a period beginning six months prior to its expiration date and up to one year after its expiration date. The right of return expires on the earlier of one year after the medicine expiration date or the time that the medicine is dispensed to the patient. The majority of medicine returns

result from medicine dating, which falls within the range set by the Company’s policy and are settled through the issuance of a credit to the customer. The Company calculates sales returns using the expected value method. The estimate of the provision for returns is based upon industry experience. This period is known to the Company based on the shelf life of medicines at the time of shipment. The Company records sales returns in “accrued expenses” and as a reduction of revenue.

Cost of Goods Sold

Distribution Service Fees

The Company includes distribution service fees paid for inventory management services as cost of goods sold. The Company calculates accrued distribution service fee estimates using the most likely amount method. The Company accrues estimated distribution fees based on contractually determined amounts. Accrued distribution service fees are included in “accrued expenses” on the condensed consolidated balance sheet.

Shipping Fees

The Company includes fees incurred by pharmacies for shipping medicines to patients as cost of goods sold. The Company calculates accrued shipping fee estimates using the expected value method. The Company records accrued shipping fees in “accrued expenses” on the condensed consolidated balance sheet.

Non-Commercial Product

The Company records the cost of non-commercial product distributed to patients as a cost of goods sold.

Royalties on Product Sales

The Company records royalty fees on the sale of commercial product as a cost of goods sold.

Recently Issued Accounting Pronouncements

In February 2016, the FASB issued ASU No. 2016-2, Leases (Topic 842) (“ASU No. 2016-2”). Under ASU No. 2016-2, an entity is required to recognize right-of-use assets and lease liabilities on its balance sheet and disclose key information about leasing arrangements. For leases with a term of twelve months or less, the lessee is permitted to make an accounting policy election not to recognize lease assets and lease liabilities by class of underlying assets. ASU No. 2016-2 became effective for the Company beginning in the first quarter of 2019. The Company adopted this standard on January 1, 2019, using a modified retrospective approach at the adoption date through a cumulative-effect adjustment to retained earnings. The adoption did not have a material impact on its condensed consolidated statement of operations. The Company elected to not recognize lease assets and liabilities for leases with an initial term of twelve months or less.

Net Income (Loss) per Common Share

Basic net loss per share is calculated by dividing the net loss by the weighted average number of common shares outstanding during the period. Diluted net loss per share is computed by dividing the net loss by the weighted average number of common shares and common stock equivalents outstanding for the period. Common stock equivalents are only included when their effect is dilutive. Potentially dilutive securities which include outstanding warrants, stock options and preferred stock have been excluded from the computation of diluted net loss per share as their effect would be anti-dilutive. For all periods presented, basic and diluted net loss were the same.

The following table presents the computation of net loss per share (in thousands, except share and per share data):



	Three Months Ended September 30,						Nine Months Ended September 30,
	2019			2018			2019			2018
Numerator
Net loss	$	(2,556	)	$	(7,779	)	$	(7,894	)	$	(13,788	)
Preferred stock dividends	(389		)	(379		)	(1,128		)	(650		)
Net Loss allocable to common stock holders	$	(2,945	)	$	(8,158	)	$	(9,022	)	$	(14,438	)
Denominator
Weighted average common shares outstanding used to compute net loss per share, basic and diluted	10,869,530			11,241,684			10,830,816			10,864,036
Net loss per share of common stock, basic and diluted
Net loss per share	$	(0.27	)	$	(0.73	)	$	(0.83	)	$	(1.33	)

Potentially dilutive securities not included in the calculation of diluted net loss per common share because to do so would be anti-dilutive are as follows:



	For the Three and Nine Months ended September 30,
	2019	2018

Stock options outstanding	4,820,407	5,380,957
Warrants	35,667,329	35,646,829
Series C Preferred Stock	68,000	68,000
Series D Preferred Stock	3,000	3,000
Series E Preferred Stock	34,780,000	34,990,000
Series F Preferred Stock	3,810,000	3,080,000
Total	79,148,736	79,168,786

Note 2 – Inventory

Inventory consists of raw material, work-in-process and finished goods stated at the lower of cost or net realizable value with cost determined on a first-in, first-out basis. The Company reviews the composition of inventory at each reporting period in order to identify obsolete, slow-moving, quantities in excess of expected demand, or otherwise non-salable items.

Inventory as of September 30, 2019 and December 31, 2018 are as follows:



	September 30, 2019		December 31, 2018
	(in thousands)
Work-in-Process	$	223	$	—
Raw Materials	73		147
Finished Goods	177		95
Inventory, Net	$	473	$	242

Note 3 - Intangible Assets

Intangible Asset Summary

Intangible assets as of September 30, 2019 are as follows:



	Net Book Value September 30, 2019		Remaining Estimated Useful Life (Years)	Annual Amortization Expense
	(in thousands)
Intangible asset - Prestalia	$	276	4.25	$	65
Intangible asset - DyrctAxess	63		11.84	5
Total	$	339		$	70

Amortization expense for the three months ended September 30, 2019 and September 30, 2018 was approximately $18,000 and $41,000, respectively. Amortization expense for the nine months ended September 30, 2019 and September 30, 2018 was approximately $53,000 and $288,000, respectively.

Note 4 – Notes Payable

On June 28, July 3, July 17, and August 5, 2019 the Company entered into term loan subscription agreements with certain accredited investors, pursuant to which the Company issued secured promissory notes (the “Notes”) in the aggregate principal amount of approximately $5.7 million. The Company paid $707,000 in debt issuance costs which was recorded as a debt discount to be amortized as interest expense over the term of the loan using the effective interest rate method.

The Notes accrue interest at a rate of 12.0% per annum. Interest is payable quarterly with the first interest payment to be made on December 28, 2019, and each subsequent payment every three months thereafter.

The unpaid principal balance of the Notes, plus accrued and unpaid interest thereon, will mature on the earliest to occur of: (i) June 28, 2020 (subject to extension for up to sixty (60) days based upon the mutual agreement of the Company and the holders of a majority of the unpaid principal balance of all outstanding Notes) or (ii) at any time following an Event of Default. The Notes may not be prepaid without the prior written consent of the holders of the Notes. The Notes are secured by a first lien and security interest on all the assets of the Company and certain of its wholly owned subsidiaries.

The Company recognized approximately and $147,000 and $148,000 in interest expense related to Notes for the three and nine months ended September 30, 2019, respectively.

Note 5 - Licensing Agreements

Les Laboratories Servier

As a result of the Asset Purchase Agreement that the Company entered into with Symplmed Pharmaceuticals LLC in June 2017, Symplmed assigned to the Company an Amended and Restated License and Commercialization Agreement with Les Laboratories Servier, pursuant to which the Company has the exclusive right to manufacture, have manufactured, develop, promote, market, distribute and sell Prestalia^® in the U.S. (and its territories and possessions). The terms of the agreement include single-digit royalty payments based on net sales and milestone payments based upon the attainment of sales thresholds. The agreement includes a termination clause pursuant to which Servier has the right to terminate the agreement in various circumstances, including, without limitation, as a result of the failure by the Company to achieve certain sales thresholds by the dates set forth in the agreement.

For the three month and nine month periods ended September 30, 2019 the Company paid $8,000 and $27,000, respectively, for royalties under the license agreement with Les Laboratories -Servier. No royalties were paid for the three or nine month periods ended September 30, 2018.

Biofarma

As consideration for the Prestalia Trademark license which the Company assumed in connection with the Asset Purchase Agreement with Symplmed, the Company pays low single digit royalties to Biofarma, an affiliate of Servier and the holder of the Prestalia trademark. For the three month and nine month periods ended September 30, 2019 the Company paid $1,000 and $3,000, respectively, to Biofarma. No royalties were paid for the three or nine month period ended September 30, 2018.

License of DiLA² Assets

On March 16, 2018, the Company entered into an exclusive sublicensing agreement for certain intellectual property rights to its DiLA2 delivery system. The agreement included an upfront payment of $200,000 and future additional consideration for sales

and development milestones. The upfront fee was contingent upon the Company obtaining a third-party consent to the agreement within ninety days of execution. As of September 30, 2019 and December 31, 2018, the Company had not obtained consent for the sublicense and has classified the upfront payment as an accrued liability on its balance sheet.

Note 6 - Related Party Transactions

Due to Related Party

The Company and other related entities have had a commonality of ownership and/or management control, and as a result, the reported operating results and/or financial position of the Company could significantly differ from what would have been obtained if such entities were autonomous.

The Company had a Master Services Agreement (“MSA”) with Autotelic Inc., a related party that is partly owned by one of the Company’s former Board members and executive officers, namely Vuong Trieu, Ph.D., effective November 15, 2016. The MSA stated that Autotelic Inc. will provide business functions and services to the Company and allowed Autotelic Inc. to charge the Company for these expenses paid on its behalf. The MSA included personnel costs allocated based on amount of time incurred and other services such as consultant fees, clinical studies, conferences and other operating expenses incurred on behalf of the Company. The MSA required a 90-day written termination notice in the event either party requires to terminate such services. We and Autotelic Inc. agreed to terminate the MSA effective October 31, 2018. Dr. Trieu resigned as a director of our company effective October 1, 2018.

During the period commencing November 15, 2016 (the “Effective Date”) and ending on the date that the Company had completed an equity offering of either common or preferred stock in which the gross proceeds therefrom is no less than $10.0 million (the “Equity Financing Date”), the Company paid Autotelic the following compensation: cash in an amount equal to the actual labor cost (paid on a monthly basis), plus 100% markup in warrants for shares of the Company’s common stock with a strike price equal to the fair market value of the Company’s common stock at the time said warrants were issued. The Company also paid Autotelic for the services provided by third party contractors plus 20% mark up. The warrant price per share was calculated based on the Black-Scholes model.

After the Equity Financing Date, the Company paid Autotelic Inc. a cash amount equal to the actual labor cost plus 100% mark up of provided services and 20% mark up of provided services by third party contractors or material used in connection with the performance of the contracts, including but not limited to clinical trial, non-clinical trial, Contract Manufacturing Organizations, FDA regulatory process, Contract Research Organizations and Chemistry and Manufacturing Controls.

In accordance with the MSA, Autotelic Inc. billed the Company for personnel and service expenses Autotelic Inc. incurred on behalf of the Company. For the nine months ended and September 30, 2018, Autotelic Inc. billed a total of approximately $778,000, including personnel costs of $371,000. No costs were billed for the period ended September 30, 2019. An unpaid balance of approximately $4,000 is included in due to related party in the accompanying balance sheets for both periods ending September 30, 2019 and December 31, 2018.

In April 2018, and in connection with the closing of our private placement on that date, we entered into a Compromise and Settlement Agreement with Autotelic Inc. pursuant to which we agreed to issue to Autotelic Inc. an aggregate of 162.59 shares of Series E Preferred Stock to settle accounts payable of $813,000 and Warrants to purchase up to 1,345,040 shares of common stock to satisfy accrued and unpaid fees in the aggregate amount of approximately $740,000, and other liabilities, owed to Autotelic Inc. as of March 31, 2018 pursuant to the MSA. The warrants have a five-year term, an initial exercise price of $0.55, and have a fair value of approximately $1.5 million resulting in a loss on settlement of debt of approximately $750,000.

Transactions with BioMauris, LLC/Erik Emerson

Until February of 2019, the Company had engaged the services of BioMauris, LLC, of which Erik Emerson, our former Chief Commercial Officer and a current director of Adhera, is Executive Chairman.

During the nine months ended September 30, 2019 and 2018, the Company recorded approximately $32,000 and $496,000, respectively, for related party expenses incurred under the agreement. As of December 31, 2018, the Company recorded approximately, $24,000 as a related party liability on the accompanying balance sheet for amounts due BioMauris, LLC. No related party liability was recorded as of September 30, 2019.

Beginning in the second quarter of 2019 when components of the financial transaction took place and fully effective in July 2019, Mr. Emerson, a member our Board of Directors and our former Chief Commercial Officer, became the owner of an equity interest of approximately 22% in Pharma Hub Network, our third-party network manager. During the third quarter of 2019, the

Company terminated the relationship with Pharma Hub Network. For the three and nine months ended September 30, 2019, the Company recorded approximately $25,000 and $62,000, respectively, of related party expense for services provided by Pharma Hub Network. No related party liability was recorded as of September 30, 2019 or December 31, 2018.

Note 7 - Stockholders’ Equity

Series E Convertible Preferred Stock Private Placement

In April and May 2018, the Company entered into Subscription Agreements with certain accredited investors and conducted a closing pursuant to which we sold 2,812 shares of our Series E Preferred, at a purchase price of $5,000 per share of Series E Preferred. Each share of Series E Preferred is initially convertible into shares of our common stock at a conversion price of $0.50 per share of common stock. In addition, each investor received a 5 year warrant to purchase 0.75 shares of common stock for each share of common stock issuable upon the conversion of the Series E Preferred purchased by such investor at an initial exercise price equal to $0.55 per share of common stock, subject to adjustment thereunder. In July of 2018, the conversion price of the warrants was adjusted down to $0.50 upon issuance of the Series F Convertible Preferred Stock. Series E Preferred accrues 8% dividends per annum which are payable in cash or stock at the Company’s discretion. The Series E Preferred has voting rights, dividend rights, liquidation preferences, conversion rights and anti-dilution rights as described in the Certificate of Designation of Preferences, Rights and Limitations of the Preferred Stock, which we filed with the Secretary of State of Delaware in April 2018. The Warrants have full-ratchet anti-dilution protection, are exercisable for a period of five years and contain customary exercise limitations.

We received net proceeds of approximately $12.2 million from the sale of the Series E Preferred, after deducting placement agent fees and estimated expenses payable by us of approximately $2.0 million associated with such closing. In connection with the private placement described above, we also issued to the placement agent for such private placement a Warrant to purchase 2,958,460 shares of our common stock.

In October 2018, an investor converted 2 shares of Series E Preferred into 20,000 shares of our common stock.

In April 2019, the Company issued 107,846 unregistered shares of our common stock to a holder of our Series E Convertible Preferred Stock in connection with the conversion of $53,923 of “Stated Value” of our Series E Convertible Preferred Stock.

As of September 30, 2019, the Company had recorded accrued dividends of approximately $2.0 million on Series E Preferred Stock.

Series F Convertible Preferred Stock Private Placement

In July 2018, the Company entered into Subscription Agreements with certain accredited investors and conducted a closing pursuant to which we sold 308 shares of our Series F Preferred, at a purchase price of $5,000 per share of Series F Preferred. Each share of Series F Preferred is initially convertible into shares of our common stock at a conversion price of $0.50 per share of common stock. In addition, each investor received a 5 year warrant (the “Warrants”, and collectively with the Preferred Stock, the “Securities”) to purchase 0.75 shares of common stock for each share of common stock issuable upon the conversion of the Series F Preferred purchased by such investor at an initial exercise price equal to $0.55 per share of common stock, subject to adjustment thereunder. The Series F Preferred accrues 8% dividends per annum which are payable in cash or stock at the Company’s discretion. The Series F Preferred has voting rights, dividend rights, liquidation preferences, conversion rights and anti-dilution rights as described in the Certificate of Designation of Preferences, Rights and Limitations of the Preferred Stock, which we filed with the Secretary of State of Delaware in July 2018. The Warrants have full-ratchet anti-dilution protection, are exercisable for a period of five years and contain customary exercise limitations.

The Company received proceeds of approximately $1.4 million from the sale of the Securities, after deducting placement agent fees and estimated expenses payable by us of approximately $180,000 associated with such closing. We used the proceeds of the offering for funding our commercial operations to the sale and promotion of our Prestalia product, working capital needs, capital expenditures, the repayment of certain liabilities and other general corporate purposes. In connection with the private placement described above, we also issued to the placement agent for such private placement a Warrant to purchase 308,000 shares of our common stock. The Warrant has a five-year term and an initial exercise price of $0.55 per share.

On November 9, 2018, the Company entered into Subscription Agreements with certain accredited investors and conducted a closing pursuant to which we sold 73 shares of our Series F Preferred Stock, at a purchase price of $5,000 per share of Preferred Stock. Each share of Series F Preferred is initially convertible into shares of our common stock at a conversion price of $0.50 per share of common stock. In addition, each investor received a 5 year warrant to purchase 0.75 shares of common stock for each share of common stock issuable upon the conversion of the Series F Preferred purchased by such investor at an initial exercise price equal to $0.55 per share of common stock, subject to adjustment thereunder. We received total net proceeds of approximately $0.3 million

from the issuance of the securities described above, after deducting placement agent fees and estimated expenses payable by us associated with such closing. In connection with the private placement described above, we also issued to the placement agent for such private placement a Warrant to purchase 73,000 shares of our common stock. The Warrant has a five-year term and an initial exercise price of $0.55 per share.

As of September 30, 2019, the Company had recorded accrued dividends of approximately $177,000 on Series F Preferred Stock.

Warrants

As of September 30, 2019, there were 35,667,329 warrants outstanding, with a weighted average exercise price of $0.63 per share, and annual expirations as follows:



Expiring in 2020	1,189,079
Expiring in 2021	343,750
Expiring in 2023	33,795,847
Expiring thereafter	338,653
Total	35,667,329

The above includes price adjustable warrants totaling 34,737,030 shares.

A total of 600,000 warrants expired during the three and nine months ended September 30, 2019.

Tender Offer - May 2019

On May 28, 2019, the Company filed a Tender Offer Statement on Schedule TO. The Schedule TO related to the offer (the “Offer”) by the Company to all holders of the Company’s outstanding warrants that were issued to investors in connection with the Company’s private placement of its Series E Convertible Preferred Stock and Series F Convertible Preferred Stock during 2018, which warrants are exercisable for shares of the Company’s common stock at an exercise price of $0.50 per share (subject to adjustment) with respect to the warrants that were issued in connection with the Company’s private placement of its Series E Convertible Preferred Stock and $0.55 per share with respect to the warrants that were issued in connection with the Company’s private placement of its Series F Convertible Preferred Stock, to receive two (2) shares of common stock in exchange for every warrant tendered by the holders thereof.

On June 6, 2019, the Company amended the Schedule TO to change the conversion terms on the issuance of warrant.

On July 2, 2019, the Company announced the termination of the exchange offer. As a result of the termination of the Offer, no Warrants were accepted for exchange or exchanged pursuant to the Offer.

Tender Offer - August 2019

On August 20, 2019, the Company filed a Tender Offer Statement on Schedule TO. The Schedule TO related to the offer by the Company to all holders of the Company’s outstanding shares of Series E Convertible Preferred Stock and Series F Convertible Preferred Stock to receive, in exchange for each share of preferred stock tendered by the holders thereof, such number of shares of common stock as is equal to the quotient obtained by dividing the “stated value” of such share of preferred stock by $0.50.

On September 26, 2019, the Company announced the termination of the Offer. As a result of the termination of the Offer, no shares of preferred stock were accepted for exchange or exchanged pursuant to the Offer.

Note 8 - Stock Incentive Plans

Stock Options

The following table summarizes stock option activity for the nine months ended September 30, 2019.



	Options Outstanding
	Shares		Weighted Average Exercise Price
Outstanding, December 31, 2018	5,613,057		$	0.83
Options granted	1,635,000		0.37
Options expired / forfeited	(2,427,650	)	0.64
Outstanding, September 30, 2019	4,820,407		0.71
Exercisable, September 30, 2019	2,986,333		$	0.76

The following table summarizes additional information on stock options outstanding at September 30, 2019.



	Options Outstanding				Options Exercisable
Range of Exercise Prices	Number Outstanding	Weighted- Average Remaining Contractual Life (Years)	Weighted Average Exercise Price		Number Exercisable	Weighted Average Exercise Price
$0.28 - $1.00	4,312,000	8.59	$	0.57	2,762,000	$	0.66
$1.50 - $1.80	493,207	7.93	$	1.79	209,133	$	1.79
$2.60 - $6.35	15,200	0.77	$	4.48	15,200	$	4.48

Totals	4,820,407	8.50	$	0.71	2,986,333	$	0.76

Weighted-Average Exercisable Remaining Contractual Life (Years) 8.09

During the nine months ended September 30, 2019, the Company granted an aggregate of 1,635,000 stock options to employees. No stock options were granted for the three month period ended September 30, 2019.

Total expense related to stock options was approximately $72,000 and $814,000 for the three months ended September 30, 2019 and 2018, respectively and approximately $708,000 and $1.3 million for the nine months ended September 30, 2019 and 2018, respectively.

As of September 30, 2019, the Company had approximately $831,000 of total unrecognized compensation expense related to unvested stock options.

As of September 30, 2019, the intrinsic value of options outstanding was zero.

Note 9 - Commitments and Contingencies

Litigation

Because of the nature of the Company’s business it is subject to claims and/or threatened legal actions, which arise out of the normal course of business. Other than the disclosure below, as of the date of this filing, the Company is not aware of any pending lawsuits against it, its officers or directors.

Paragraph IV Challenge

The Company’s Prestalia product was involved in a paragraph IV challenge regarding patents issued to perindopril arginine. This challenge, which was pending in the United States District Court for the District of Delaware (No. 1:17-cv-276), was captioned Apotex Inc. and Apotex Corp. v. Symplmed Pharmaceuticals, LLC and Les Laboratoires Servier. The challengers (Apotex Inc. and Apotex Corp. (“Apotex”)) filed an Abbreviated New Drug Application seeking FDA approval to market a generic version of Prestalia and included a Paragraph (IV) certification. In the litigation, Apotex sought a declaratory judgment that no valid claims of the two patents the Company listed in the FDA Orange Book as having claims covering Prestalia, U.S. Patent No. 6,696,481 and 7,846,961, will be infringed by the Apotex proposed generic version of Prestalia and that the claims of those patents are invalid. The challenge was designed to provide Apotex with an opportunity to enter the market with a generic version of Prestalia, ahead of the expiration of the patents with claims covering that product.

Servier (which entity owns or controls intellectual property rights relating to Prestalia^®, which rights have been licensed to the Company to resolve the challenge in the second quarter of 2017. Such parties, along with us, have reached an agreement on terms that result in a delay to the challengers’ ability to enter the market with a generic version of Prestalia, while still providing the challenger with the right to enter the market prior to the expiration of the patent covering such product. Specifically, the parties have entered into a Confidential Settlement Agreement in connection with the settlement of the matter, pursuant to which, among other things, the parties entered into a Confidential License Agreement, whereby Symplmed, Servier and our company agreed to grant to Apotex a non-transferable, non-sublicensable, perpetual, irrevocable, royalty-free, non-exclusive license to the two patents listed in the FDA Orange Book as having claims covering Prestalia to make, use and market a generic version of Prestalia, or import a generic version of Prestalia from India into the United States, on or after January 1, 2021.

As a result of the foregoing, the matter is now settled.

Leases

The Company entered into a Standard Form Office Lease with ROC III Fairlead Imperial Center, LLC, as landlord, pursuant to which we lease our corporate headquarters located at 4721 Emperor Boulevard, Suite 350, Durham, North Carolina 27703 for a term of 37 months starting on October 1, 2018. Our base monthly rent for such space is currently $6,458, which amount will increase to $7,057 for the final month of the term. Other than the lease for our corporate headquarters, we do not own or lease any real property or facilities that are material to our current business operations. As we expand our business operations, we may seek to lease additional facilities of our own in order to support our operational and administrative needs under our current operating plan.

The Company adopted ASU No. 2016-2 on January 1, 2019, using a modified retrospective approach at the adoption date through a cumulative-effect adjustment to retained earnings. The adoption did not have a material impact on its condensed consolidated statement of operations. However, the new standard required the Company to establish approximately $0.2 million of liabilities and corresponding right-of-use assets of approximately $0.2 million on its condensed consolidated balance sheet for operating leases on rented office properties that existed as of the January 1, 2019, adoption date. The total right-of-use asset was approximately $157,000 as of September 30, 2019 and is reflected in the operating lease right of use asset on the accompanying condensed consolidated balance sheet. The total related liability was approximately $165,000 as of September 30, 2019, of which approximately $77,000 is included in current portion of operating lease liability and approximately $88,000 is reflected in operating lease liability, net of current portion on the accompanying condensed consolidated balance sheet.

Note 10 - Subsequent Events

Except for the events discussed below, there were no subsequent events that required recognition or disclosure. The Company evaluated subsequent events through the date the financial statements were issued and filed with the Securities and Exchange Commission.

On October 30, 2019, the Company repurchased 20 shares of Series F Convertible Preferred Stock including accrued and unpaid dividends and warrants to purchase 150,000 shares of common stock for $100,000 from our former CEO pursuant to an amendment to the settlement agreement dated April 4, 2019. The Company also committed to purchase from such officer the remaining Series F Convertible Preferred Stock and related warrants for $100,000 by not later than March 1, 2020.

On November 1, 2019, the Company issued 350,000 stock options to an employee at exercise price of $.09 per share. The grant included both time and performance based vesting.

On November 19, 2019, the Company entered into an Amendment No. 4 to the Amended and Restated License and Commercialization Agreement with Les Laboratories Servier, which modified the agreement to delay the date by which the Company would be required to meet certain net sales milestones as set forth in the agreement. As per the license and commercialization agreement, as amended, Les Laboratories Servier may terminate the agreement if net sales of Prestalia^® by the Company are below $1.0 million for two successive calendar quarters beginning after June 30, 2020.

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations

Forward-Looking Statements

This Quarterly Report on Form 10-Q includes a number of forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933, as amended (the “Securities Act”), and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), that reflect management’s current views with respect to future events and financial performance. The following discussion should be read in conjunction with the financial statements and related notes contained in our Annual Report on Form 10-K, as filed with the Securities and Exchange Commission (“SEC”) on

April 16, 2019. Forward-looking statements are projections in respect of future events or financial performance. In some cases, you can identify forward-looking statements by terminology such as “may,” “should,” “expects,” “plans,” “anticipates,” “believes,” “estimates,” “predicts,” “potential” or “continue” or the negative of these terms or other comparable terminology.

Forward-looking statements are inherently subject to risks and uncertainties, many of which we cannot predict with accuracy and some of which we might not even anticipate. Although we believe that the expectations reflected in such forward-looking statements are based upon reasonable assumptions at the time made, we can give no assurance that such expectations will be achieved. Future events and actual results, financial and otherwise, may differ materially from the results discussed in the forward-looking statements. Readers are cautioned not to place undue reliance on these forward-looking statements. We undertake no obligation to publicly update or revise any forward-looking statements after the date of this Quarterly Report on Form 10-Q or to conform them to actual results, new information, future events or otherwise, except as otherwise required by securities and other applicable laws.

The following factors, among others, could cause our or our industry’s future results to differ materially from historical results or those anticipated:


•	our ability to obtain additional and substantial funding for our company on an immediate basis, whether pursuant to a capital raising transaction arising from the sale of our securities, a strategic transaction or otherwise;


•	our ability to repay or restructure any outstanding indebtedness owed by our company to third parties, including the indebtedness represented by the secured promissory notes that we issued between June and August 2019, or to convert such indebtedness into the equity securities of our company;


•	our ability to attract and/or maintain research, development, commercialization and manufacturing partners, including, in particular, Les Laboratories Servier (from which company we license rights with respect to our Prestalia product), and to fulfill our obligations under any agreements that we have entered into with such partners, such that such agreements remain in full force and effect;


•	the ability of our company and/or a partner to successfully complete product research and development, including pre-clinical and clinical studies and commercialization;


•	the ability of our company and/or a partner to obtain and maintain required governmental approvals, including product patent approvals, and to comply with all required regulatory and reporting obligations with respect thereto;


•	the ability of our company and/or a partner to develop and commercialize products that can compete favorably with those of our competitors;


•	the timing of costs and expenses related to the research and development programs of our company and/or our partners;


•	the timing and recognition of revenue from milestone payments and other sources not related to product sales;


•	our ability to obtain suitable facilities in which to conduct our planned business operations on acceptable terms and on a timely basis;


•	our ability to satisfy our disclosure obligations under the Securities Exchange Act of 1934, as amended, and to maintain the registration of our common stock thereunder;


•	our ability to attract and retain qualified officers, employees and consultants as necessary; and


•	costs associated with any product liability claims, patent prosecution, patent infringement lawsuits and other lawsuits.

These statements are only predictions and involve known and unknown risks, uncertainties and other factors, including the risks in the section entitled “Risk Factors” set forth in our Annual Report on Form 10-K for the year ended December 31, 2018, as filed with the SEC on April 16, 2019, any of which may cause our company’s or our industry’s actual results, levels of activity, performance or achievements to be materially different from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. These risks may cause our or our industry’s actual results, levels of activity or performance to be materially different from any future results, levels of activity or performance expressed or implied by these forward-looking statements.

Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, levels of activity or performance. Moreover, neither we nor any other person assumes responsibility for the accuracy and completeness of these forward-looking statements. We are under no duty to update any forward-looking statements after the date of this report to conform these statements to actual results.

As used in this quarterly report and unless otherwise indicated, the terms “we,” “us,” “our” or the “Company” refer to Adhera Therapeutics, Inc., a Delaware corporation, and its wholly-owned subsidiaries, MDRNA Research, Inc., Cequent Pharmaceuticals, Inc., Atossa Healthcare, Inc., and IthenaPharma, Inc. Unless otherwise specified, all dollar amounts are expressed in United States dollars. Our common stock is currently listed on the OTC Market, OTCQB tier, under the symbol “ATRX.”

Corporate Overview

Nature of Business

We are an emerging specialty pharmaceutical company that leverages innovative distribution models and technologies to improve the quality of care for patients in the United States suffering from chronic diseases. We are focused on fixed dose combination (“FDC”) therapies in hypertension, with plans to expand the portfolio of drugs we commercialize to include other therapeutic areas.

Our mission is to provide effective and patient centric treatment for hypertension and resistant hypertension while actively seeking additional assets that can be commercialized through our proprietary Total Care System (“TCS”). At the core of our TCS is DyrctAxess, our patented technology platform. DyrctAxess is designed to offer enhanced efficiency, control and access to the information necessary to empower patients, physicians and manufacturers to achieve optimal care.

We began marketing Prestalia^®, a single-pill FDC of perindopril arginine (“perindopril”) and amlodipine besylate (“amlodipine”) in June of 2018. By combining Prestalia^®, DyrctAxess and an independent pharmacy network, we have created a proprietary system for drug adherence and the effective treatment of hypertension, improving the distribution of FDC hypertensive drugs, such as our FDA-approved product Prestalia^®, as well as improving the distribution of devices for therapeutic drug monitoring (“TDM”) (e.g., blood pressure monitors), as well as patient counseling and prescription reminder services. We are focused on demonstrating the therapeutic and commercial value of our TCS through the commercialization of Prestalia^®. Prestalia^® was developed in coordination with Les Laboratories Servier, a French pharmaceutical conglomerate, that sells the formulation outside the United States under the brand names Coveram^® and/or Viacoram^®. Prestalia^® was approved by the U.S. Food and Drug Administration (“FDA”) in January 2015 and is distributed through our DyrctAxess platform, which we acquired in 2017.

By combining Prestalia, DyrectAxess, and a specialty pharma network, we have created a proprietary platform for drug adherence and the effective treatment of hypertension, improving the distribution of FDC hypertensive drugs, such as our FDA-approved product Prestalia, devices for therapeutic drug monitoring (e.g., blood pressure and other cardiac monitors), as well as patient counseling and prescription reminder services.

As our strategy is to be a commercial pharmaceutical company, we will drive a primary corporate focus on revenue generation through our commercial assets, while continuing to develop our technology platform and TCS. We intend to create value through the expanded commercialization of our FDA-approved product, Prestalia®, while continuing to develop and leverage our TCS to further strengthen our commercial presence.

On September 4, 2019, we entered into a Co-Promotion Agreement with Allegis Pharmaceuticals, LLC (“Allegis”) to co-promote Allegis’ FDA approved product Nitrolingual^® Pumpspray, indicated for acute relief of an attack or prophylaxis of angina pectoris due to coronary artery disease. The Co-Promotion Agreement relates to both the branded and the authorized generic versions of the product.

Results of Operations

Comparison of the Three Months Ended September 30, 2019 to the Three Months Ended September 30, 2018

Net Sales

We recorded net sales of approximately $51,000, net of related discounts for the three months ended September 30, 2019 compared to net sales of approximately $135,000 for the three-month period ended September 30, 2018. The decrease in sales represents revenues from the sale of Prestalia^®. The reduction in sales was primarily due to our strategic decision to transition to a new pharmacy network during the quarter which will reduce costs and provide nationwide distribution of Prestalia® and our production supply issues including production delays and serialization activities.

Cost of Sales

Cost of sales were $106,000 for the three months ended September 30, 2019 compared to $67,000 for the three months ended September 30, 2018, and represents cost of sales from the sale of Prestalia^®. The increase in cost of sales was primarily due to an increase in the cost of services provided by the pharmacy network utilized for the three month period ended September 30, 2019 as compared to the three months ended September 30, 2018.

Operating Expenses

Our operating expenses for the three months ended September 30, 2019 and 2018 are summarized as follows:



	Three Months Ended
	September 30, 2019		September 30, 2018		Increase/(Decrease)
	(in thousands)
Sales and marketing	$	1,311	$	871	$	440
General and administrative expenses	840		2,141		(1,301		)
Goodwill and intangible asset impairment	—		4,794		(4,794		)
Amortization	18		41		(23		)
Total operating expenses	$	2,169	$	7,847	$	(5,678	)

Sales, Marketing and Commercial Operations

For the three months ended September 30, 2019, sales, marketing and commercial operations expense increased by approximately $440,000 as compared to the prior period, primarily due to our digital marketing campaign and other marketing related activities for Prestalia^® and regulatory consulting costs incurred for manufacturing serialization.

General and Administrative

General and administrative expense decreased by approximately $1.3 million for the three months ended September 30, 2019, as compared to the three months ended September 30, 2018, primarily due to decrease in share-based compensation of approximately $737,000 and reorganization costs of $282,000 incurred for the three months ended September 30, 2018 compared to no reorganization cost for the same period of 2019.

Goodwill and intangible asset impairment

During the three months ended September 30, 2019, the Company determined that an intangible asset and goodwill was impaired and, as a result, a loss on impairment of $4.8 million was recognized for the three-month period ended September 30, 2018. The impairment determination was primarily a result of the decision to divest of assets that no longer align with the Company’s strategic objectives. There was no such loss on impairment for the three months ended September 30, 2019.

Amortization Expense

Amortization of intangible assets decreased by approximately $23,000 for the three-month period ended September 30, 2019 primarily due to the write-off of intangibles in 2018 as a result of our decision to divest assets that no longer align with our strategic objectives.

Other Expense



	Three Months Ended
	September 30, 2019			September 30, 2018		(Increase)/Decrease
	(in thousands)
Interest expense	$	(332	)	$	—	$	(332	)
Loss on settlement	—			—		—
Total other expense, net	$	(332	)	$	—	$	(332	)

Total net other expense for the three months ended September 30, 2019 increased by $332,000 compared to the three months ended September 30, 2018 primarily due to accrued interest and amortization of debt issuance costs for our term loan.

Comparison of the Nine Months Ended September 30, 2019 to the Nine Months Ended September 30, 2018

Net Sales

We recorded net sales of approximately $120,000 for the nine months ended September 30, 2019 as compared to approximately $135,000 for the nine months ended September 30, 2018, which represents revenues from the sale of Prestalia®. The reduction in sales was primarily due to our strategic decision to transition to a new pharmacy network during the third quarter of

2019 which will reduce costs and provide nationwide distribution of Prestalia® and our production supply issues including production delays and serialization activities.

Cost of Sales

Cost of sales were approximately $304,000 for the nine months ended September 30, 2019 as compared to $67,000 for the nine months ended September 30, 2018, which represents cost of sales from the sale of Prestalia®. The increase in cost of sales was primarily due to an increase in the cost of services provided by the pharmacy network utilized for the nine month period ended September 30, 2019 as compared to the nine months ended September 30, 2018.

Operating Expenses

Our operating expenses for the nine months ended September 30, 2019 are summarized as follows in comparison to our expenses for the nine months ended September 30, 2018.



	Nine Months Ended
	September 30, 2019		September 30, 2018		Increase/(Decrease)
	(in thousands)
Sales and marketing	$	3,518	$	3,457	$	61
Research and development	—		173		(173		)
General and administrative expenses	3,806		4,120		(314		)
Goodwill and intangible asset impairment	—		4,794		(4,794		)
Amortization	53		288		(235		)
Total operating expenses	$	7,377	$	12,832	$	(5,455	)

Sales, Marketing and Commercial Operations

For the nine months ended September 30, 2019, sales, marketing and commercial operations expense increased by approximately $61,000, as compared to the prior period, primarily due to our digital marketing campaign related to the sales of Prestalia®.

Research and Development

For the nine months ended September 30, 2019, research and development expense decreased by approximately $173,000, as compared to the nine months ended September 30, 2018 due to the transition of our strategic focus from R&D activities to sales, marketing and commercial operations activities beginning in the second quarter of 2018.

General and Administrative

General and administrative expense decreased by approximately $314,000 for the nine months ended September 30, 2019, as compared to the nine months ended September 30, 2018, primarily due to a decrease in stock based compensation expense offset by severance payments made to executive management during the nine months ended September 30, 2019.

Goodwill and intangible asset impairment

During the nine months ended September 30, 2018, the Company determined that an intangible asset and goodwill was impaired and, as a result, a loss on impairment of $4.8 million was recognized for the nine-month period ended September 30, 2018. The impairment determination was primarily a result of the decision to divest of assets that no longer align with the Company’s strategic objectives. There was no such loss on impairment for the nine months ended September 30, 2019.

Amortization Expense

Amortization of intangible assets decreased by approximately $235,000 for the nine-month period ended September 30, 2019 primarily due to the write-off of intangibles in 2018 as a result of our decision to divest assets that no longer align with our strategic objectives.

Other Expense



	Nine Months Ended
	September 30, 2019			September 30, 2018			(Increase)/Decrease
	(in thousands)
Interest expense	$	(333	)	$	(149	)	$	(184	)
Loss on settlement	—			(875		)	875
Total other expense, net	$	(333	)	$	(1,024	)	$	691

Total net other expense for the nine months ended September 30, 2019 decreased approximately $691,000 compared to the nine months ended September 30, 2018 primarily due to a loss on settlement of a related party liability for the nine months ended September 30, 2018 as compared to the same period of 2019. Interest expense for the nine months ended September 30, 2019, included approximately $148,000 for interest expense and amortization of debt issuance costs for our term loan.

Liquidity & Capital Resources

Working Capital



(in thousands)	September 30, 2019			December 31, 2018
Current assets	$	3,578		$	4,677
Current liabilities	(9,432		)	(2,214		)
Working (deficit) capital	$	(5,854	)	$	2,463

Negative working capital as of September 30, 2019 was approximately $5.9 million as compared to working capital of approximately $2.5 million as of December 31, 2018. The decrease in working capital is primarily related to an increase in our current liabilities as of September 30, 2019 including approximately $5.2 million of notes payable net of issuance costs, an increase in accrued dividends for our convertible preferred stock of approximately $1.1 million and an increase in accounts payable and accrued expenses related to our operating activities.

Cash Flows and Liquidity

Net cash used in Operating Activities

Net cash used in operating activities was approximately $6.2 million during the nine months ended September 30, 2019. This was primarily due to our net operating loss of approximately $7.9 million, partially offset by non-cash share-based compensation of approximately $0.7 million and other changes in operating assets and liabilities including an increase in accounts payable and accrued expenses.

Comparatively, net cash used in operating activities was approximately $7.0 million during the nine months ended September 30, 2018. This was primarily due to the net operating loss of approximately $13.8 million offset by non-cash charges of approximately $4.8 million for impairment of goodwill and intangible asset impairment and approximately $2.0 million for other changes in working capital including $1.3 million of non-cash share-based compensation.

Net cash used in Investing Activities

There was no cash used in or provided by investing activities for the nine months ended September 30, 2019. Cash used in investing activities for the period ended September 30, 2018 was approximately $28,000 for the purchase of furniture for the corporate office.

Net cash provided by Financing Activities

Net cash provided by financing activities for the nine months ended September 30, 2019 was approximately $5.0 million from the issuance of promissory notes to certain accredited investors during the second and third quarters of 2019. For the nine months ended September 30, 2018, cash provided by financing activities was approximately $13.4 million primarily due to the issuance of preferred stock.

We will need to raise additional operating capital during the fourth quarter of 2019 in order to maintain our operations and to realize our business plan. Without additional sources of cash and/or the deferral, reduction, or elimination of significant planned expenditures, we will not have the cash resources to continue as a going concern thereafter.

Future Financing

We will require immediate substantial additional funds to implement our strategic initiatives and continue the commercialization of Prestalia®. Historically, we have raised additional capital to supplement our commercialization, clinical development and operational expenses. We will need to raise substantial additional funds required through equity financing, debt financing, strategic alliances or other sources, which may result in further dilution in the equity ownership of our shares. There can be no assurance that additional financing will be available when needed or, if available, that it can be obtained on commercially reasonable terms. Failure to raise additional capital through one or more financings, divesting development assets or reducing discretionary spending could have a material adverse effect on our ability to achieve our intended business objectives. These factors raise substantial doubt about our ability to continue as a going concern.

Off-Balance Sheet Arrangements

As of September 30, 2019, we did not have any off-balance sheet arrangements, as defined in Item 303(a)(4)(ii) of SEC Regulation S-K.

Critical Accounting Policies and Estimates

Our significant accounting policies are more fully described in the notes to our financial statements included herein for the period ended September 30, 2019 and in the notes to our consolidated financial statements included in our Annual Report on Form 10-K for the year ended December 31, 2018.

New and Recently Adopted Accounting Pronouncements

Any new and recently adopted accounting pronouncements are more fully described in Note 1 to our financial statements included herein for the period ended September 30, 2019.

ITEM 3 QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

Not applicable.

ITEM 4 CONTROLS AND PROCEDURES

Evaluation of Disclosure Controls and Procedures

We maintain disclosure controls and procedures (as that term is defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act that are designed to ensure that information required to be disclosed in our reports under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms, and that such information is accumulated and communicated to our management, including our principal executive officer and principal financial officer, as appropriate, to allow timely decisions regarding required disclosures. In designing disclosure controls and procedures, our management necessarily was required to apply its judgment in evaluating the cost-benefit relationship of possible disclosure controls and procedures. The design of any disclosure controls and procedures also is based in part upon certain assumptions about the likelihood of future events, and there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions. Any controls and procedures, no matter how well designed and operated, can provide only reasonable, not absolute, assurance of achieving the desired control objectives.

Our management, with the participation of our principal executive officer and principal financial officer, has evaluated the effectiveness of the design and operation of our disclosure controls and procedures as of the end of the period covered by this report. Based upon that evaluation and subject to the foregoing, our principal executive officer and principal financial officer concluded that, our disclosure controls and procedures were not effective due to the material weakness(es) in internal control over financial reporting described below.

Material Weakness in Internal Control over Financial Reporting

Management conducted an assessment of the effectiveness of our internal control over financial reporting as of September 30, 2019 based on the framework established in Internal Control—Integrated Framework (2013) issued by the Committee of

Sponsoring Organizations of the Treadway Commission. Based on this assessment, management has determined that our internal control over financial reporting as of September 30, 2019 was not effective.

A material weakness, as defined in the standards established by the Sarbanes-Oxley Act of 2002 (the “Sarbanes-Oxley Act”), is a deficiency, or a combination of deficiencies, in internal control over financial reporting such that there is a reasonable possibility that a material misstatement of our annual or interim financial statements will not be prevented or detected on a timely basis.

The ineffectiveness of our internal control over financial reporting was due to the following material weaknesses which are indicative of many small companies with small number of staff:


•	Inadequate segregation of duties consistent with control objectives;


•	Lack of qualified accounting personnel to prepare and report financial information in accordance with GAAP; and


•	Lack of documentation on policies and procedures that are critical to the accomplishment of financial reporting objectives.

Management’s Plan to Remediate the Material Weakness

Management has been implementing and continues to implement measures designed to ensure that control deficiencies contributing to the material weakness are remediated, such that these controls are designed, implemented, and operating effectively. The remediation actions planned include:


•	Identify gaps in our skills base and the expertise of our staff required to meet the financial reporting requirements of a public company; and


•	Continue to develop policies and procedures on internal control over financial reporting and monitor the effectiveness of operations on existing controls and procedures.

During the three months ended September 30, 2019, we continued to execute upon our planned remediation actions which are all intended to strengthen our overall control environment. Our Company and all subsidiaries use a well-regarded accounting software which restricts personnel access and standardizes daily accounting procedures on journal entries. The software includes built-in controls and documentation to facilitate accounting review of the books and records. Our Audit Committee continues to exercise oversight responsibilities related to financial reporting and internal control. In November of 2019, we hired an executive with GAAP and financial reporting expertise to assist in the preparation of financial reporting.

The aforementioned measures taken are expected to lead to an improvement in the timely preparation of financial reports and to strengthen our segregation of duties at the Company. We are committed to maintaining a strong internal control environment, and we believe that these remediation efforts will represent significant improvements in our control environment. Our management will continue to monitor and evaluate the relevance of our risk-based approach and the effectiveness of our internal controls and procedures over financial reporting on an ongoing basis and is committed to taking further action and implementing additional enhancements or improvements, as necessary and as funds allow.

Changes in Internal Control over Financial Reporting

There have been no changes in our internal control over financial reporting (as defined in Rule 13a-15(f) and 15d-15(f) under the Exchange Act) during the fiscal quarter ended September 30, 2019 that have materially affected, or that are reasonably likely to materially affect, our internal control over financial reporting.

PART II – OTHER INFORMATION

ITEM 1. LEGAL PROCEEDINGS

Paragraph IV Challenge

Our Prestalia product was involved in a paragraph IV challenge regarding patents issued to perindopril arginine. This challenge, which was pending in the United States District Court for the District of Delaware (No. 1:17-cv-00276), was captioned Apotex Inc. and Apotex Corp. v. Symplmed Pharmaceuticals, LLC and Les Laboratoires Servier. The challengers (Apotex Inc. and Apotex Corp. (“Apotex”)) filed an Abbreviated New Drug Application seeking FDA approval to market a generic version of Prestalia^® and included a Paragraph (IV) certification. In the litigation, Apotex sought a declaratory judgment that no valid claims of the two patents Symplmed listed in the FDA Orange Book as having claims covering Prestalia^®, U.S. Patent No. 6,696,481 and 7,846,961, will be infringed by the Apotex proposed generic version of Prestalia and that the claims of those patents are invalid. The challenge was designed to provide Apotex with an opportunity to enter the market with a generic version of Prestalia, ahead of the expiration of the patents with claims covering that product.

Apotex entered into negotiations with Symplmed Pharmaceuticals, LLC (which entity sold its assets relating to Prestalia^® to us in June 2017, including its License and Commercialization Agreement with Les Laboratories Servier) and Les Laboratories Servier (which entity owns or controls intellectual property rights relating to Prestalia^®,which rights have been licensed to our company, to resolve the challenge in the second quarter of 2017. Such parties, along with us, have reached an agreement on terms that result in a delay to the challengers’ ability to enter the market with a generic version of Prestalia, while still providing the challenger with the right to enter the market prior to the expiration of the patent covering such product. Specifically, the parties have entered into a Confidential Settlement Agreement in connection with the settlement of the matter, pursuant to which, among other things, the parties entered into a Confidential License Agreement, whereby Symplmed, Servier and our company agreed to grant to Apotex a non-transferable, non-sublicensable, perpetual, irrevocable, royalty-free, non-exclusive license to the two patents listed in the FDA Orange Book as having claims covering Prestalia to make, use and market a generic version of Prestalia, or import a generic version of Prestalia from India into the United States, on or after January 1, 2021.

As a result of the foregoing, the matter is now settled.

General

Currently, there is no material litigation pending against our company other than as disclosed above. From time to time, we may become a party to litigation and subject to claims incident to the ordinary course of our business. Although the results of such litigation and claims in the ordinary course of business cannot be predicted with certainty, we believe that the final outcome of such matters will not have a material adverse effect on our business, results of operations or financial condition. Regardless of outcome, litigation can have an adverse impact on us because of defense costs, diversion of management resources and other factors.

ITEM 1A. RISK FACTORS

An investment in our common stock involves a number of very significant risks. You should carefully consider the risk factors included in the “Risk Factors” section of our Annual Report on Form 10-K for the fiscal year ended December 31, 2018 (the “Annual Report”), as filed with the SEC on April 16, 2019, in addition to other information contained in those documents and reports that we have filed with the SEC pursuant to the Securities Act and the Exchange Act since the date of the filing of the Annual Report, including, without limitation, this Quarterly Report on Form 10-Q, and the additional risk factors noted below, in evaluating our company and its business before purchasing shares of our common stock. Our business, operating results and financial condition could be adversely affected due to any of those risks.

We are dependent upon Prestalia^® for our ability to generate revenue from the sale of products, and we are dependent upon Les Laboratoires Servier for our rights to Prestalia^®.

Our ability to generate revenue from the sale of drug products is currently dependent primarily upon sales of Prestalia^®. Prestalia^®is the primary product to which we have rights that has been approved for sale. Although we acquired the rights from Allegis Pharmaceuticals, LLC during the third quarter of 2019 to co-promote Allegis’ Nitrolingual Pumpspray, sales of Prestalia^® accounted for 100% of our product revenue during the first three quarters of 2019. We do not anticipate that any of our other product candidates would be approved for sale in the near term, if at all, as currently we are not expending resources on the development of any other product candidates, though we may acquire rights to approved products as a result of our product acquisition efforts. Our rights to Prestalia^® derive from the license and commercialization agreement between our company and Les Laboratoires Servier. As per such agreement, as amended, Les Laboratoires Servier has the right in various circumstances to terminate the agreement, including, without limitation, if net sales of Prestalia^® are below $1.0 million for two successive calendar quarters beginning after June 30, 2020. If our license and commercialization agreement with Les Laboratoires Servier were to be terminated or materially modified for any reason, or if our rights to Prestalia^® were to be reduced or eliminated for any reason other than the termination of the license and commercialization agreement, our revenues and business operations would be materially adversely affected, which would likely have a significant impact on the trading price of our common stock.

ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS

None.

ITEM 3. DEFAULTS UPON SENIOR SECURITIES

None.

ITEM 4. MINE SAFETY DISCLOSURES

None.

ITEM 5. OTHER INFORMATION

None.

Item 6. Exhibits



Exhibit No.		Description

4.1		Form of Secured Promissory Note issued by Adhera Therapeutics, Inc. to select accredited investors on each of June 28, 2019, July 3, 2019, July 17, 2019 and August 5, 2019 (filed as Exhibit 4.1 to our Current Report on Form 8-K dated June 28, 2019, and incorporated herein by reference).

10.1		Security Agreement, dated as of June 28, 2019, among Adhera Therapeutics, Inc., IThenaPharma, Inc., Cequent Pharmaceuticals, Inc., MDRNA Research, Inc., the purchasers of secured promissory notes identified on the signature pages thereto that were issued on June 28, 2019, July 3, 2019, July 17, 2019 and August 5, 2019, and Jeff S. Phillips as agent (filed as Exhibit 10.1 to our Current Report on Form 8-K dated June 28, 2019, and incorporated herein by reference).

10.2		Form of Subscription Agreement used in connection with the issuance by Adhera Therapeutics, Inc. of Secured Convertible Promissory Notes on each of June 28, 2019, July 3, 2019, July 17, 2019 and August 5, 2019 (filed as Exhibit 10.2 to our Current Report on Form 8-K dated August 5, 2019, and incorporated herein by reference).

31.1		Certification of Principal Executive Officer pursuant to Rule 13a-14 and 15d-14 under the Securities Exchange Act of 1934, as amended. (1)

32.1		Certification of Principal Financial Officer pursuant to Rule 13a-14 and 15d-14 under the Securities Exchange Act of 1934, as amended. (1)

31.2		Certification of Principal Executive Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002. (2)
32.2		Certification of Principal Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002. (2)

101INS		XBRL Instance Document (1)

101SCH		XBRL Taxonomy Extension Schema Document (1)

101CAL		XBRL Taxonomy Extension Calculation Linkbase Document (1)

101DEF		XBRL Taxonomy Extension Definition Linkbase Document (1)

101LAB		XBRL Taxonomy Extension Label Linkbase Document (1)

101PRE		XBRL Taxonomy Extension Presentation Linkbase Document (1)

(1)		Filed herewith.
(2)		Furnished herewith.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.



	ADHERA THERAPEUTICS, INC.

Date: November 19, 2019	By:	/s/ Nancy R. Phelan.
		Nancy R. Phelan Chief Executive Officer and Director (Principal Executive Officer)





Date: November 19, 2019	By:	/s/ Rhonda Stanley
		Rhonda L. Stanley Senior Vice President of Finance (Principal Financial Officer and Principal Accounting Officer)